| Madaser Saleem, DO | |
|
4755 Ogletown Stanton Rd Ste 1070, Newark, DE 19718-2200 | |
| (302) 733-1663 | |
| (302) 733-4533 |
| Full Name | Madaser Saleem |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 4755 Ogletown Stanton Rd Ste 1070, Newark, Delaware |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134611262 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 25MB11015100 (New Jersey) | Secondary |
| 207R00000X | Internal Medicine | C2-0024119 (Delaware) | Primary |
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
Certain chromosomal abnormalities of the preleukemic type appear to be over-represented in patients with type 2 diabetes (T2D) who are suffering from vascular complications. This finding may provide a partial explanation for the higher rates of cancer-related mortality observed among patients with this type of diabetes.
To coincide with the twentieth anniversary of the enactment of the Americans with Disabilities Act today, President Obama is joining the Ad Council and the American Association of People with Disabilities to launch a new series of television and radio public service advertisements. The ads, which feature the President, celebrate the progress that has been made during the last two decades and remind the public that there is still a lot of work to do so that all Americans have equal opportunity and full participation in this country.
› Verified 3 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245474329 PECOS PAC ID: 9739097569 Enrollment ID: O20091027000729 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
Certain chromosomal abnormalities of the preleukemic type appear to be over-represented in patients with type 2 diabetes (T2D) who are suffering from vascular complications. This finding may provide a partial explanation for the higher rates of cancer-related mortality observed among patients with this type of diabetes.
To coincide with the twentieth anniversary of the enactment of the Americans with Disabilities Act today, President Obama is joining the Ad Council and the American Association of People with Disabilities to launch a new series of television and radio public service advertisements. The ads, which feature the President, celebrate the progress that has been made during the last two decades and remind the public that there is still a lot of work to do so that all Americans have equal opportunity and full participation in this country.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madaser Saleem, DO 4755 Ogletown Stanton Rd Ste 1070, Newark, DE 19718-2200 Ph: (302) 733-1663 | Madaser Saleem, DO 4755 Ogletown Stanton Rd Ste 1070, Newark, DE 19718-2200 Ph: (302) 733-1663 |
News Archive
Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
Certain chromosomal abnormalities of the preleukemic type appear to be over-represented in patients with type 2 diabetes (T2D) who are suffering from vascular complications. This finding may provide a partial explanation for the higher rates of cancer-related mortality observed among patients with this type of diabetes.
To coincide with the twentieth anniversary of the enactment of the Americans with Disabilities Act today, President Obama is joining the Ad Council and the American Association of People with Disabilities to launch a new series of television and radio public service advertisements. The ads, which feature the President, celebrate the progress that has been made during the last two decades and remind the public that there is still a lot of work to do so that all Americans have equal opportunity and full participation in this country.
› Verified 3 days ago
Shruti Puri, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 Fax: 302-733-5640 | |
Zaid A Ammari, M.D. M.P.H. Internal Medicine Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1000 Fax: 347-851-8707 | |
Dr. Suresh Trivedi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 Continental Dr, Suite 406, Newark, DE 19713 Phone: 302-368-2630 Fax: 302-368-1271 | |
Dr. Bradley Bley, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1096 Old Churchmans Rd, Newark, DE 19713 Phone: 302-655-9494 Fax: 302-351-4898 | |
Dr. Avinash Chandra, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 86 Omega Dr, Omega Professional Center, Building B-86, Newark, DE 19713 Phone: 302-366-1929 Fax: 302-366-1006 | |
Dr. Lucinda Li, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 4755 Ogletown Stanton Rd Ste 5a43, Newark, DE 19718 Phone: 302-623-0188 | |
Dr. James Robinson Mcninch Iv, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1148 |